November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Intravitreal anti-VEGF drugs are step forward in AMD management
December 15th 2005The promise of 2004, that new anti-vascular endothelial growth factor (VEGF) treatments for age-related macular degeneration (AMD) be developed, came to fruition in 2005, much to the excitement of ophthalmologists. These emerging treatments for AMD took center stage this year and resulted in numerous ideas about the effect of the pharmaceutical advancements and their impact on other retinal diseases.
Read More
Prodrug is target-specific therapy for cataracts
November 15th 2005Chicago—Nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) is a significant advance in the treatment of pain and inflammation associated with cataract surgery. The nonsteroidal anti-inflammatory prodrug offers well-tolerated, effective, target-specific therapy that may enhance patient compliance and quality of vision outcomes, said Robert P. Lehmann, MD, FACS, at the annual meeting of the American Academy of Ophthalmology.
Read More
New approach to AMD turns off disease-causing genes
November 15th 2005A new and promising therapeutic approach to treating diseases in which abnormal protein production is a problem, including AMD, is known as RNA interference (RNAi). RNAi is a biological method of turning off specific disease-causing genes and is being tested in at least two trials involving patients with AMD.
Read More
Research into the genetics of ocular disease is paying off with discoveries of new genes associated with both common and rare eye conditions. Gene therapy, however, could be 5 to 10 years away for many eye diseases. In this first of a two-part series, researchers explain the progress in age-related macular degeneration (AMD), Leber's congenital amaurosis, and familial exudative vitreoretinopathy (FEVR). In the second half of the series, gains in glaucoma, myopia, and retinitis pigmentosa will be covered as well as a promising therapy for AMD—RNA interference.
Read More
First patient enrolled in phase III pegaptanib trial for DME, diabetic retinopathy
October 17th 2005Eyetech Pharmaceuticals Inc. announced on Monday the enrollment of the first patient in a phase III randomized, controlled, double-masked, multicenter, comparative dose-finding trial that will compare the safety and efficacy of pegaptanib sodium injection (Macugen) in patients with diabetic macular edema (DME).
Read More
Pegaptanib sodium data promising for DME, other retinal vascular diseases
October 15th 2005The preliminary pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals) exploratory phase II data indicate that the drug seems to be successful for treating diabetic macular edema (DME), according to Steven Schwartz, MD, who reported the findings of the Macugen Diabetic Retinopathy Study Group during the retina subspecialty day at the American Academy of Ophthalmology annual meeting.
Read More
VEGF inhibitor found promising for DME
October 15th 2005Montr?al—The exploratory phase II trial of pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals/Pfizer) for the treatment of diabetic macular edema (DME) showed that the drug is safe, effective, and well tolerated. The patients who received the 0.3-mg dose of pegaptanib sodium achieved a better visual acuity level than those who received sham treatment, and they had more of a reduction in the central retinal thickness.
Read More
Ranibizumab fast-track designation denied; Genentech plans to file complete application
October 1st 2005South San Francisco—Genentech Inc. said it intends to file a complete Biologics License Application (BLA) in December for its ranibizumab (Lucentis) treatment for the wet form of age-related macular degeneration (AMD). In addition, the company said it was recently notified that the FDA denied a request for fast-track designation for the investigational drug, which would allow for a rolling BLA submission.
Read More
Merger of OSI, Eyetech solidifies research
October 1st 2005New York—The $935 million acquisition of Eyetech Pharmaceuticals Inc. by OSI Pharmaceuticals Inc. will boost research and development (R&D) opportunities for both companies, while preserving Eyetech's integrity as a stand-alone business unit, according to leaders of both organizations.
Read More
Crystalens update reports improved vision outcomes, possible new mechanism of action
September 12th 2005Lisbon, Portugal - Recent data on the crystalens accommodating IOL (eyeonics) indicate there is a slight-but-noticeable improvement in distance and near visual performance as follow-up is lengthening. The results also suggest an additional mechanism of action may account for the better-than-expected near vision outcomes being seen in some patients, said Steven Dell, MD.
Read More
Low-dose corticosteroid targets acute allergic conjunctivitis
September 1st 2005Orangeburg, NY—The low-dose modified corticosteroid loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is effectively used during the acute phase of seasonal allergic conjunctivitis, according to Ayman Matta, MD, PC, FACS.
Read More
Pegaptanib earns praise as 'product of the year'
September 1st 2005New York—Pegaptanib sodium injection (Macugen) has won recognition as a major scientific breakthrough from an organization accustomed to novel pharmaceutical products. The drug, the first FDA-approved treatment for wet age-related macular degeneration (AMD), was named Innovative Pharmaceutical Product of the Year at the 2005 Pharmaceutical Achievement Awards.
Read More
Topical NSAID enhances patient response during cyclosporine induction therapy
August 15th 2005Fort Lauderdale, FL—Ketorolac tromethamine 0.4% ophthalmic solution (Acular LS, Allergan) may be a useful adjunct for improving patient comfort and treatment compliance during the induction phase of dry eye therapy with cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan), Barry A. Schechter, MD, said to colleagues at the annual meeting of the Association for Research in Vision and Ophthalmology here.
Read More
AMD research takes aim at choroidal neovascularization
August 15th 2005Los Angeles—The medical management of age-related macular generation (AMD) has progressed by leaps and bounds in a very short space of time and generated a great deal of excitement among retina specialists. In particular, translational research has resulted in a large number of drugs that target choroidal neovascularization (CNV).
Read More